Comparative Pharmacology
Head-to-head clinical analysis: ATORVALIQ versus ZYPITAMAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVALIQ versus ZYPITAMAG.
ATORVALIQ vs ZYPITAMAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATORVALIQ is a combination of atorvastatin and amlodipine. Atorvastatin is an HMG-CoA reductase inhibitor that decreases cholesterol synthesis in the liver. Amlodipine is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
ZYPITAMAG (pitavastatin magnesium) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced intracellular cholesterol and upregulation of LDL receptors.
10-80 mg orally once daily. Starting dose 10-20 mg. Max dose 80 mg.
2-4 mg orally once daily, at any time of day, with or without food.
None Documented
None Documented
The terminal elimination half-life of atorvastatin is approximately 14 hours; however, its active metabolites have a half-life of 20-30 hours, allowing for once-daily dosing.
Terminal elimination half-life: 12 hours (range 10-14 h) in healthy subjects; supports once-daily dosing
Atorvastatin is primarily eliminated via biliary/fecal excretion (approximately 70% as metabolites), with renal excretion accounting for less than 2% of the administered dose.
Primarily renal (93% as unchanged pitavastatin and metabolites) via active tubular secretion; fecal (5%)
Category C
Category C
Statin
Statin